Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18919079 | 0.93 | MAPT (0.63) | MAPTSIGMAR1KMT2AALDH1A1DRD2 | |
| SCHEMBL18919126 | 0.93 | MAPT (0.59) | MAPTSIGMAR1KMT2AALDH1A1DRD2 | |
| SCHEMBL18919154 | 0.91 | MAPT (0.60) | MAPTSIGMAR1KMT2AALDH1A1DRD2 | |
| SCHEMBL18919147 | 0.88 | MAPT (0.56) | MAPTKMT2AALDH1A1DRD2DRD3 | |
| SCHEMBL18919127 | 0.86 | RXFP1 (0.56) | MAPTKMT2AALDH1A1DRD2DRD3 | |
| SCHEMBL17444646 | 0.85 | POLB (0.54) | MAPTSIGMAR1KMT2AALDH1A1DRD2 | |
| SCHEMBL18889417 | 0.85 | POLB (0.54) | MAPTSIGMAR1KMT2AALDH1A1DRD2 | |
| SCHEMBL18919115 | 0.83 | SIGMAR1 (0.54) | MAPTSIGMAR1KMT2AALDH1A1HRH3 | |
| SCHEMBL18919117 | 0.83 | SIGMAR1 (0.54) | MAPTSIGMAR1KMT2AALDH1A1HRH3 | |
| SCHEMBL17444644 | 0.81 | SIGMAR1 (0.52) | MAPTSIGMAR1KMT2AALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157135-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157135-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | MAPT 2167/4885SIGMAR1 2217/4885KMT2A 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.